RxDoctor Payments DataLook up a doctor →

Rachel Korson, MD

Neurology · Murray, KYNPI 1568635134

Payments from drug & device makers

$16,722in general payments, 2019–2025

Across 1,033 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Eisai Inc.$974
  • Pfizer$911
  • CSL Behring$755
  • AstraZeneca$747
  • Amgen$731
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$680%
  • Food & beverage$16,17397%
  • Education$4813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)201$2,127
Eisai Inc.42$974
Pfizer70$911
CSL Behring35$755
AstraZeneca22$747
Amgen44$731
Acadia Pharmaceuticals Inc36$668
Novartis47$636
EMD Serono, Inc.34$617
Neurocrine Biosciences, Inc.24$604
SK Life Science, Inc.29$554
Biogen36$552
Supernus Pharmaceuticals, Inc.35$544
Lilly USA, LLC34$534
Biohaven Pharmaceuticals, Inc.54$513
Jazz Pharmaceuticals Inc.23$440
Avanir Pharmaceuticals, Inc.21$433
Lundbeck LLC23$401
Biohaven Pharmaceutical Holding Company Ltd.33$368
Harmony Biosciences LLC14$308
Vanda Pharmaceuticals Inc.10$250
Axsome Therapeutics, Inc.13$239
Genentech USA, Inc.11$237
Mallinckrodt Hospital Products Inc.14$230
Teva Pharmaceuticals USA, Inc.5$180
Amneal Pharmaceuticals LLC11$170
Sumitomo Pharma America, Inc.10$157
Sanofi8$143
Bristol Myers Squibb9$136
UCB, Inc.4$114
ANI Pharmaceuticals, Inc.5$111
Cycle Pharmaceuticals Inc6$108
GE HealthCare4$105
Argenx US, Inc.4$84
Neurelis, Inc.4$84
Mallinckrodt Enterprises LLC5$73
Johnson & Johnson4$71
Acorda Therapeutics, Inc4$68
Philips North America LLC4$68
Inspire Medical Systems, Inc.3$62
Tanabe Pharma America, Inc.3$61
Zyla Life Sciences, Inc.4$51
E.r. Squibb & Sons, L.L.C.4$50
Otsuka America Pharmaceutical, Inc.3$49
Collegium Pharmaceutical, Inc.3$48
Kyowa Kirin, Inc.3$48
Takeda Pharmaceuticals U.S.A., Inc.2$40
Adamas Pharmaceuticals, Inc.2$35
Grifols USA, LLC2$31
Portola Pharmaceuticals, LLC2$30
Catalyst Pharmaceuticals, Inc.1$25
Aquestive Therapeutics, Inc.1$23
Sunovion Pharmaceuticals Inc.1$20
Abbott1$17
Resmed Corp1$16
Arbor Pharmaceuticals, Inc.1$15
Livanova USA, Inc.1$15
Banner Life Sciences, LLC1$13
Boehringer Ingelheim1$13
Avion Pharmaceuticals1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,722 in reported general payments places this provider in the 75th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$161,150
Medicare patients
536
Services billed
6,526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5034$322,482
TecfideraDimethyl Fumarate25$225,975
Kesimpta PenOfatumumab25$209,628
CopaxoneGlatiramer Acetate30$206,274
IngrezzaValbenazine Tosylate11$120,009
BetaseronInterferon Beta-1b12$115,158
ZeposiaOzanimod Hydrochloride13$108,102
AmpyraDalfampridine25$106,467
Nurtec OdtRimegepant Sulfate55$81,050
Emgality PenGalcanezumab-Gnlm71$57,827
QuliptaAtogepant18$34,428
UbrelvyUbrogepant24$27,566
RytaryCarbidopa/Levodopa13$21,378
KeppraLevetiracetam12$13,512
Memantine Hcl543$13,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$755$322,48234 claims
BiogenTecfidera$552$225,97525 claims
Teva Pharmaceuticals USA, Inc.Copaxone$180$206,27430 claims
Neurocrine Biosciences, Inc.Ingrezza$604$120,00911 claims
E.r. Squibb & Sons, L.L.C.Zeposia$50$108,10213 claims
Acorda Therapeutics, IncAmpyra$68$106,46725 claims
PfizerNurtec Odt, Eliquis$911$93,13972 claims
AbbVieQulipta, Ubrelvy$2,127$61,99442 claims
Amneal Pharmaceuticals LLCRytary$170$21,37813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 210 neurology providers in Kentucky.

Other neurology in Murray

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →